Balyasny Asset Management LLC Immunity Bio, Inc. Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 65,811 shares of IBRX stock, worth $221,124. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,811
Previous 207,196
68.24%
Holding current value
$221,124
Previous $1.31 Million
81.36%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding IBRX
# of Institutions
212Shares Held
70.1MCall Options Held
1.64MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$56.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$38.4 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$29.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$12.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$7.55 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.35B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...